Literature DB >> 10755549

In vivo T-cell depletion enhances production of anti-GALalpha1,3GAL natural antibodies in alpha1,3-galactosyltransferase-deficient mice.

H Ohdan1, Y G Yang, K G Swenson, A D Thall, M Sykes.   

Abstract

BACKGROUND: It has been reported that T-cell depletion by in vivo treatment with monoclonal antibodies results in polyclonal B-cell activation. However, its effects on B cells responding to Galalpha1,3Gal (Gal) epitopes remain unknown.
METHODS: alpha1,3-Galactosyltransferase-deficient (GalT-/-) mice were treated with depleting anti-CD4 and CD8 monoclonal antibodies. The kinetics of anti-Gal natural antibodies (NAb) and total immunoglobulin levels in their sera were evaluated. The frequencies of anti-Gal NAb-producing cells were determined in the various tissues of GalT-/- mice by enzyme-linked immunospot assay.
RESULTS: In vivo T-cell depletion led to significant increases in both anti-Gal IgM and total IgM levels in sera of GalT-/- mice, but did not influence either anti-Gal IgG or total IgG levels. An increased frequency of anti-Gal and total IgM-producing cells was observed in the spleens and bone marrow of T-cell-depleted GalT-/-mice but not in peritoneal cavity cells.
CONCLUSION: In vivo T-cell depletion facilitates anti-Gal IgM production, suggesting that T cells deliver inhibitory signals to B cells responding to Gal.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755549     DOI: 10.1097/00007890-200003150-00041

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study.

Authors:  Hidetaka Hara; Andrew Bentall; Cassandra Long; Jason Fang; Oleg Andreyev; John Lunz; Mohamed Ezzelarab; Kareem M Abu-Elmagd; Ron Shapiro; David Ayares; Mark Stegall; David K C Cooper
Journal:  Xenotransplantation       Date:  2013-09-03       Impact factor: 3.907

2.  T-cell-based immunosuppressive therapy inhibits the development of natural antibodies in infant baboons.

Authors:  Eefje M Dons; Claudia Montoya; Cassandra E Long; Hidetaka Hara; Gabriel J Echeverri; Burcin Ekser; Corin Ezzelarab; Dasha Roa Medellin; Dirk J van der Windt; Noriko Murase; Lora H Rigatti; Robert Wagner; Roman F Wolf; Mohamed Ezzelarab; Lori J West; Jan N M Ijzermans; David K C Cooper
Journal:  Transplantation       Date:  2012-04-27       Impact factor: 4.939

3.  B-cell extrinsic CR1/CR2 promotes natural antibody production and tolerance induction of anti-alphaGAL-producing B-1 cells.

Authors:  Ichiro Shimizu; Toshiyasu Kawahara; Fabienne Haspot; Philip D Bardwell; Michael C Carroll; Megan Sykes
Journal:  Blood       Date:  2006-10-05       Impact factor: 22.113

Review 4.  IXA Honorary Member Lecture, 2017: The long and winding road to tolerance.

Authors:  Megan Sykes
Journal:  Xenotransplantation       Date:  2018-05       Impact factor: 3.907

5.  Are there advantages in the use of specific pathogen-free baboons in pig organ xenotransplantation models?

Authors:  Huidong Zhou; Hayato Iwase; Roman F Wolf; Burcin Ekser; Mohamed Ezzelarab; Hidetaka Hara; Gary White; David K C Cooper
Journal:  Xenotransplantation       Date:  2014-02-18       Impact factor: 3.907

6.  High antigen levels do not preclude B-cell tolerance induction to alpha1,3-Gal via mixed chimerism.

Authors:  Fabienne Haspot; Philip D Bardwell; Guiling Zhao; Megan Sykes
Journal:  Xenotransplantation       Date:  2008 Sep-Oct       Impact factor: 3.907

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.